Canada Orders $434 Million-Worth of Monkeypox Vax Even Though Country Reports Only 1,363 Cases and WHO Says Outbreak Is on ‘Downward Trend’

Vaccine manufacturer enters 10-year contract with Canada.

  • Monkeypox vaccine manufacturer Bavarian Nordic announced on Tuesday it revised its contract with the Public Health Agency of Canada (PHAC) to supply doses of “Imvamune” (“Jynneos” in the U.S.) smallpox/monkeypox vaccine at a value of approximately $234 million in addition to $180 million in contract options.
  • “This extends the USD 56 million contract awarded in June 2022 to a total value of up to USD 470 million,” danish biotechnology company Bavarian Nordic stated in a press release. “Furthermore, a new multi-year contract has been signed with Canada’s Department of National Defence (DND) at a value of USD 2 million, in addition to USD 18 million in contract options.”
  • Canada has only reported 1,363 monkeypox infections as of Sep 16 out of a population of 38,000,000. And the World Health Organization (WHO) recently announced Canada’s monkeypox outbreak is showing a “downward trend,” which was characterized by WHO director-general Dr. Tedros Adhanom Ghebreyesus as “encouraging to see.” Despite this, the majority of the vaccine order supply will not even be delivered until 2023 and the country has agreed to an option to procure additional doses annually until 2032.

Bavarian Nordic president and CEO Paul Chaplin praised Canada’s decision, valued at nearly half a billion dollars: “With foresight and prioritization, Canada has shown the way to building a robust preparedness for its population. As a trusted supplier of smallpox vaccines to the Canadian authorities since 2008, we are pleased to extend and expand our collaboration for the next decade, thus helping to maintain the readiness for Canada to respond quickly to emergencies, such as the current monkeypox outbreak.”

  • American Faith is compiling a list of concerns regarding Bavarian Nordic’s monkeypox vaccine which are being ignored by the mainstream media:
  • The FDA package insert for Bavarian Nordic’s monkeypox vaccine says that heart problems of “special interest” occur in 1 in 75 vaccine recipients who have not already been vaccinated against smallpox, but also in 1 in 48 vaccine recipients who have already been vaccinated against smallpox. The insert indicates Bavarian Nordic added “tromethamine,” a drug given to treat heart attacks, to the vaccine.
  • The CDC reported how one in four women (25%) who became pregnant after being injected with Bavarian Nordic’s monkeypox vaccine suffered a “spontaneous abortion.”
  • The monkeypox vaccine insert also says the vaccine “has not been evaluated” for “[i]mpairment of male fertility.”
  • It is not known whether Bavarian Nordic’s monkeypox vaccine is excreted in human breastmilk: “Data are not available to assess the effects of JYNNEOS in the breastfed infant or on milk production/excretion,” according to the FDA insert.
  • The insert also warns that the monkeypox vaccine “has not been evaluated for carcinogenic or mutagenic potential,” meaning it is unknown whether the vaccine causes cancer or genetic mutations in humans.
  • MIT reported earlier this month how Bavarian Nordic’s vice president of clinical strategy, Heinz Weidenthaler, admitted the effectiveness of the company’s monkeypox vaccine has not yet been tested: “[W]e’ve simply had no opportunity to test this in humans,” said Weidenthaler.
  • There are no long-term studies evaluating how the monkeypox vaccine will interact with the COVID-19 vaccine itself already linked to heart disease (herehereherehere).
  • The WHO has admitted that the monkeypox vaccine is “not 100% effective” against the virus.
  • Last month, the WHO reported a number of “breakthrough cases” of monkeypox infections were occurring among the vaccinated, meaning the vaccine failed to protect from the virus.
  • There are 23,893 confirmed monkeypox cases in the United States as of Sep 19, according to the Centers for Disease Control and Prevention (CDC).
  • A senior Chinese health official on Saturday advised people to avoid contact with foreigners to prevent monkeypox infection after the first known case of the virus on mainland China was reported, Reuters notes. “To prevent possible monkeypox infection and as part of our healthy lifestyle, it is recommended that 1) you do not have direct skin-to-skin contact with foreigners,” Wu Zunyou, chief epidemiologist at the China Center for Disease Control and Prevention posted on his official Weibo page.
  • The official also called for people to avoid such contact with people who have been abroad within the past three weeks as well as all “strangers,” as he cautioned vigilance.